Adolescents and young adults; strong male predominance (about 4:1)
Fewer than 1 per million per year
Last audited: 2026-08-13 against NCCN, ESMO, and WHO 5th ed. guidelines.
Clinical Presentation & Hallmark Symptoms
Presenting signs most frequently observed across clinical case series
Genomic Profiling & Defining Molecular Lesions
Critical diagnostic fusions, somatic mutations, and therapeutic targets
Rare malignancies frequently depend on distinct oncogenic drivers rather than conventional environmental carcinogens. Comprehensive Next-Generation Sequencing (NGS comprehensive panel) and FISH/IHC are mandatory to establish the true diagnosis and screen for basket trial agents.
Standard-of-Care Treatment Protocol
Frontline and multimodal strategies established under international consensus guidelines
Multi-agent chemotherapy (P6-type regimens with alkylating agents)
Administered in specialized high-volume oncology programs with subspecialty pathology and organ-preservation protocols.
Aggressive cytoreductive surgery aiming for near-complete debulking
Administered in specialized high-volume oncology programs with subspecialty pathology and organ-preservation protocols.
Hyperthermic intraperitoneal chemotherapy (HIPEC) in selected patients
Administered in specialized high-volume oncology programs with subspecialty pathology and organ-preservation protocols.
Whole-abdominopelvic radiotherapy
Administered in specialized high-volume oncology programs with subspecialty pathology and organ-preservation protocols.
Clinical trial enrolment
Administered in specialized high-volume oncology programs with subspecialty pathology and organ-preservation protocols.
Prognosis & Disease Trajectory
Objective clinical outlook without false reassurance
Note: Statistics reflect cohort averages. Individual outcomes depend heavily on performance status, resectability, biomarker expression, and timely access to specialized tertiary care.
Active Research, Biomarkers & Clinical Trials
Novel investigational agents, phase I/II trials, and international rare disease consortia
Targeting the EWSR1-WT1 fusion directly, IGF1R inhibition, WT1-directed immunotherapy and vaccine approaches are all under investigation.
Need Help Matching to an Active Rare Cancer Trial?
ByOnco scans ClinicalTrials.gov, NCI trial networks, and institutional registries for open patient cohorts.
Verified Specialists for Desmoplastic Small Round Cell Tumor
Dr. Andrea Hayes-Jordan
Pediatric Surgical Oncologist
UNC (formerly MD Anderson)
Chapel Hill, USA
Dr. Richard Quek
Senior Consultant Medical Oncologist
NCCS (formerly)
Singapore, Singapore
Prof. Jeremy Whelan
Medical Oncologist
UCLH
London, United Kingdom
Dr. Sameer Rastogi
Sarcoma Medical Oncologist
AIIMS, New Delhi
New Delhi, India
Designated Cancer Centers with Dedicated Programs
NCI-Designated Comprehensive Cancer Center
World-leading rare tumor board & pediatric solid tumor protocols
NCI-Designated Comprehensive Cancer Center
Largest specialized rare cancer and sarcoma multidisciplinary program
NCI-Designated Comprehensive Cancer Center
Pioneering genomic molecular tumor boards & rare histologies
NCI-Designated Comprehensive Cancer Center
High-volume surgical oncology & rare endocrine/neuroendocrine expertise
Frequently Asked Clinical Questions
Authoritative guidance on diagnosis, tumor boards, genomic markers, and care options
Related Rare Malignancies in Catalog
Facing a Diagnosis of Desmoplastic Small Round Cell Tumor?
Rare cancers demand rare expertise. Connect your medical records to US NCI-fellowship trained oncologists, subspecialist pathologists, and active clinical trial investigators within 12 to 72 hours.